Temporal spectrum of ischemic complications with percutaneous coronary intervention: The ESPRIT experience

Warren J. Cantor, James E. Tcheng, James C. Blankenship, J. Conor O'Shea, Karen S. Pieper, Douglas A. Criger, Mina Madan, John Ducas, William S. Sheldon, Mark A. Tannenbaum, Jack E. Smith, Michael M. Kitt, Ian Gilchrist

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We determined the timing of ischemic complications within 30 days after percutaneous coronary intervention (PCI) in patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial. Complications (death, myocardial infarction [MI], target vessel revascularization) occurred in 178 of 2064 patients (8.6%) within 30 days. More than 85% of complications occurred within the 24 hours following randomization, with the greatest risk hazard at 12-18 hours. Unexpectedly, 31% of patients who ultimately met criteria for an endpoint MI within 24 hours of PCI had completely normal CK-MB concentrations at the first 6-hour measurement. There was no "rebound" increase in events after cessation of eptifibatide. Treatment benefit persisted to 30 days. Post-procedural MI is often not detected until ≥ 12 hours after PCI. Treatment with a glycoprotein IIb/IIIa inhibitor is the only modifiable parameter that reduces the risk for early ischemic complications.

Original languageEnglish (US)
Pages (from-to)475-481
Number of pages7
JournalJournal of Invasive Cardiology
Volume16
Issue number9
StatePublished - Sep 1 2004

Fingerprint

Percutaneous Coronary Intervention
Blood Platelets
Myocardial Infarction
Platelet Glycoprotein GPIIb-IIIa Complex
Random Allocation
Therapeutics
eptifibatide

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Cantor, W. J., Tcheng, J. E., Blankenship, J. C., O'Shea, J. C., Pieper, K. S., Criger, D. A., ... Gilchrist, I. (2004). Temporal spectrum of ischemic complications with percutaneous coronary intervention: The ESPRIT experience. Journal of Invasive Cardiology, 16(9), 475-481.
Cantor, Warren J. ; Tcheng, James E. ; Blankenship, James C. ; O'Shea, J. Conor ; Pieper, Karen S. ; Criger, Douglas A. ; Madan, Mina ; Ducas, John ; Sheldon, William S. ; Tannenbaum, Mark A. ; Smith, Jack E. ; Kitt, Michael M. ; Gilchrist, Ian. / Temporal spectrum of ischemic complications with percutaneous coronary intervention : The ESPRIT experience. In: Journal of Invasive Cardiology. 2004 ; Vol. 16, No. 9. pp. 475-481.
@article{b634fd5bb593437cbfec596ba8f5fa73,
title = "Temporal spectrum of ischemic complications with percutaneous coronary intervention: The ESPRIT experience",
abstract = "We determined the timing of ischemic complications within 30 days after percutaneous coronary intervention (PCI) in patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial. Complications (death, myocardial infarction [MI], target vessel revascularization) occurred in 178 of 2064 patients (8.6{\%}) within 30 days. More than 85{\%} of complications occurred within the 24 hours following randomization, with the greatest risk hazard at 12-18 hours. Unexpectedly, 31{\%} of patients who ultimately met criteria for an endpoint MI within 24 hours of PCI had completely normal CK-MB concentrations at the first 6-hour measurement. There was no {"}rebound{"} increase in events after cessation of eptifibatide. Treatment benefit persisted to 30 days. Post-procedural MI is often not detected until ≥ 12 hours after PCI. Treatment with a glycoprotein IIb/IIIa inhibitor is the only modifiable parameter that reduces the risk for early ischemic complications.",
author = "Cantor, {Warren J.} and Tcheng, {James E.} and Blankenship, {James C.} and O'Shea, {J. Conor} and Pieper, {Karen S.} and Criger, {Douglas A.} and Mina Madan and John Ducas and Sheldon, {William S.} and Tannenbaum, {Mark A.} and Smith, {Jack E.} and Kitt, {Michael M.} and Ian Gilchrist",
year = "2004",
month = "9",
day = "1",
language = "English (US)",
volume = "16",
pages = "475--481",
journal = "Journal of Invasive Cardiology",
issn = "1042-3931",
publisher = "HMP Communications",
number = "9",

}

Cantor, WJ, Tcheng, JE, Blankenship, JC, O'Shea, JC, Pieper, KS, Criger, DA, Madan, M, Ducas, J, Sheldon, WS, Tannenbaum, MA, Smith, JE, Kitt, MM & Gilchrist, I 2004, 'Temporal spectrum of ischemic complications with percutaneous coronary intervention: The ESPRIT experience', Journal of Invasive Cardiology, vol. 16, no. 9, pp. 475-481.

Temporal spectrum of ischemic complications with percutaneous coronary intervention : The ESPRIT experience. / Cantor, Warren J.; Tcheng, James E.; Blankenship, James C.; O'Shea, J. Conor; Pieper, Karen S.; Criger, Douglas A.; Madan, Mina; Ducas, John; Sheldon, William S.; Tannenbaum, Mark A.; Smith, Jack E.; Kitt, Michael M.; Gilchrist, Ian.

In: Journal of Invasive Cardiology, Vol. 16, No. 9, 01.09.2004, p. 475-481.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Temporal spectrum of ischemic complications with percutaneous coronary intervention

T2 - The ESPRIT experience

AU - Cantor, Warren J.

AU - Tcheng, James E.

AU - Blankenship, James C.

AU - O'Shea, J. Conor

AU - Pieper, Karen S.

AU - Criger, Douglas A.

AU - Madan, Mina

AU - Ducas, John

AU - Sheldon, William S.

AU - Tannenbaum, Mark A.

AU - Smith, Jack E.

AU - Kitt, Michael M.

AU - Gilchrist, Ian

PY - 2004/9/1

Y1 - 2004/9/1

N2 - We determined the timing of ischemic complications within 30 days after percutaneous coronary intervention (PCI) in patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial. Complications (death, myocardial infarction [MI], target vessel revascularization) occurred in 178 of 2064 patients (8.6%) within 30 days. More than 85% of complications occurred within the 24 hours following randomization, with the greatest risk hazard at 12-18 hours. Unexpectedly, 31% of patients who ultimately met criteria for an endpoint MI within 24 hours of PCI had completely normal CK-MB concentrations at the first 6-hour measurement. There was no "rebound" increase in events after cessation of eptifibatide. Treatment benefit persisted to 30 days. Post-procedural MI is often not detected until ≥ 12 hours after PCI. Treatment with a glycoprotein IIb/IIIa inhibitor is the only modifiable parameter that reduces the risk for early ischemic complications.

AB - We determined the timing of ischemic complications within 30 days after percutaneous coronary intervention (PCI) in patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial. Complications (death, myocardial infarction [MI], target vessel revascularization) occurred in 178 of 2064 patients (8.6%) within 30 days. More than 85% of complications occurred within the 24 hours following randomization, with the greatest risk hazard at 12-18 hours. Unexpectedly, 31% of patients who ultimately met criteria for an endpoint MI within 24 hours of PCI had completely normal CK-MB concentrations at the first 6-hour measurement. There was no "rebound" increase in events after cessation of eptifibatide. Treatment benefit persisted to 30 days. Post-procedural MI is often not detected until ≥ 12 hours after PCI. Treatment with a glycoprotein IIb/IIIa inhibitor is the only modifiable parameter that reduces the risk for early ischemic complications.

UR - http://www.scopus.com/inward/record.url?scp=4544367473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544367473&partnerID=8YFLogxK

M3 - Article

C2 - 15353828

AN - SCOPUS:4544367473

VL - 16

SP - 475

EP - 481

JO - Journal of Invasive Cardiology

JF - Journal of Invasive Cardiology

SN - 1042-3931

IS - 9

ER -

Cantor WJ, Tcheng JE, Blankenship JC, O'Shea JC, Pieper KS, Criger DA et al. Temporal spectrum of ischemic complications with percutaneous coronary intervention: The ESPRIT experience. Journal of Invasive Cardiology. 2004 Sep 1;16(9):475-481.